Idiopathic (Essential) Hypertension - Pipeline Review, H2 2012 New Report
Idiopathic (Essential) Hypertension - Pipeline Review, H2 2012, provides an overview of the Idiopathic (Essential) Hypertension therapeutic pipeline. This report provides information on the therapeutic development for Idiopathic (Essential) Hypertension, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Idiopathic (Essential) Hypertension. 'Idiopathic (Essential) Hypertension - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC...
View full press release